

Herbal Anti Diabetic A Review Efficacy and Mechanisms

Kamlesh Shinde, Suresh Waghmare, Nikhil Nikam, Siddhesh Chavan, Pranjali Lahare

Rashtriya College of Pharmacy, Hatnoor, Kannad, Sambhajinagar, Maharashtra, India

Abstract: *People of different age groups are affected by diabetes, a chronic physiological dysfunction that severely disrupts people's normal lives all around the world. There is a pressing need for the identification and development of novel antidiabetic medications due to the development of resistance and adverse effects of long-term use of insulin treatments and a number of synthetic vocal antidiabetic therapies. On the down side, scientists, researchers, and pharmaceutical companies around the world are increasingly turning to stores or herbal sources in their search for implicit bioactive emulsions in order to find and create new, targeted antidiabetic medications that can control diabetes with the fewest side effects of conventional antidiabetic medications. We provided the potential campaigners with a single phytochemical in this review. or unrefined extract that contains bioactive phytoconstituents with notable antidiabetic potential that have been documented in a number of in vitro, in vivo, and clinical investigations. Based on the reported phytochemicals and/or factory excerpts, the similar behavior patterns described here have been attributed to antidiabetic conditioning.*

They also punctuate some inquisitive phytochemicals and phytosources for future research into the identification and development of novel antidiabetic rectifiers. Keywords: medication detection, medicine evolution, phytochemical, phytomedicine, diabetes mellitus, antidiabetic, and antihyperglycemic.

Keywords: diabetes mellitus, antidiabetic, antihyperglycemic, phytochemical, phytomedicine, bioactive compound, drug discovery, drug development

I. INTRODUCTION

Diabetes mellitus is a kind of chronic metabolic disease that is caused by inadequate insulin exertion and/or insulin storage. When insulin, an anabolic hormone, is absent, abnormalities in the metabolism of proteins, carbs, and fats may result (1). These metabolic anomalies are mostly brought on by low insulin levels, target apkins' insulin resistance, and the location of the insulin receptor. adipose tissue, cadaverous muscles, and, to a lesser extent, the liver, signal transduction system, effector enzymes, genes, and/or signal transduction pathway (2). Approximately 2.8 percent of people worldwide suffer from diabetes, one of the most prevalent metabolic diseases. It is expected to rise to 4.4 percent by 2030, reaching an unknown level of epidemic prevalence (3). Despite being a non-communicable disease, diabetes is ranked among the top five global morbidities (1). Symptom inflexibility determines the order and frequency of diabetes. While some people with diabetes, especially those with type 2 diabetes in the early stages of the disease, have no symptoms, others have noticeable hyperglycemia. Because of ketoacidosis or uncommon non-ketonic hyperosmolar illnesses, untreated and unmonitored diabetes can cause torpor, coma, and even death if left untreated (4). Diabetes may arise as a result of both hereditary and non-genetic causes (5). This is always unclear, even though the diabetes bracket is crucial and affects treatment plans. About ten of the first classified instances may require change later on, and many diabetes individuals do not easily fit into a single class; instead, they are young adults (6). The American Diabetes Association's (ADA) 1997 introduction of the standard bracket of diabetes as type 1, type 2, and gravid diabetes mellitus (GDM) is still the most widely recognized and supported by the ADA(4). Many antidiabetic medications are already on the market to treat hyperglycemia; these medications specifically function by improving insulin sensitivity, finishing insulin, increasing insulin storage, and promoting glucose absorption. However, a number of undesirable side effects are associated with antidiabetic medications of the metformin and sulfonylureas types, such as lactic acidosis and diarrhea (shown by metformin) and hepatic failure, weight gain, tachycardia, and hypothyroidism

(shown by sulfonylureas) (7). A factory is usually regarded as one of the most reliable sources of agents that cure ailments, and many of those synthetic medications are derived from them directly or indirectly. Based on recent research, stores and factory products can offer potential antidiabetic efficacy (Figure 1).

Factory sources of antidiabetic chemicals are veritably vital popular from the ancient time as they're pretty safer and much cheaper druthers than synthetic medicines and are also mentioned in numerous folklore pharmaceuticals including the Indian, Korean and Chinese culture. Traditional herbal drugs and functional foods are believed to meliorate diabetic runs via six notable medium of conduct including enhanced insulin stashing and perceptivity, glucose uptake by muscle cells and adipose apkins and inhibition of glucose immersion from intestine and glucose product from hepatocytes along with demonstrating anti-inflammatory parcels(7). As a result, functional foods and phytotherapies are growing popular across the world day by day(8). To provide unique insight into the development of novel functional foods and medication components against diabetes, we have compiled the most prominent pharmaceutical and health-promoting stores in the current review, together with their insulated antidiabetic phytochemicals. Figure 2 displays the handwriting at its most pictorial level.




Figure 1 Graphical abstract of prospective antidiabetic phytochemicals from medicinal plants for the discovery and development

Diabetes mellitus

To better understand diabetes mellitus (DM), it is necessary to understand the metabolic process by which the body uses energy from food. Importantly, the food that is consumed is broken down into a simpler form called glucose, which gives the body energy. The body uses blood vessels as its primary means of transporting sugar because sugar cannot enter cells on its own. The pancreas is the most important organ behind the stomach because it produces insulin hormone, which acts as a carrier and allows sugar to enter cells (9). Without insulin hormone conflation, sugar cannot enter the body's cells, resulting in high blood sugar levels, a condition known as hyperglycemia. Furthermore, a lack of insulin can result in an excess of reactive oxygen species (ROS), which can cause B-cell dysfunction and other secondary problems (such as increased thirst, hunger, cardiac problems, order failure, bottom ulcers, and eye damage). The mechanistic approach states that hyperglycemia causes the production of reactive oxygen species (ROS) by activating many pathways, including as the polyol and hexosamine pathway, the protein kinase C (PKC) pathway, and the AGE/RAGE (advanced glycation end products and their receptor) mechanism. Overproduction of ROS triggers the apoptotic pathway by causing inflammation and oxidative damage. Under comparable circumstances, they decrease the bioavailability of nitric oxide (NO), which causes endothelial and vascular dysfunction. Insulin conflation is inhibited as a result, leading to diabetes complaints. Figure 5(10). For the operation and treatment of diabetes, innovative cures that don't have unwanted side effects are therefore desperately needed. In order to develop efficient methods for finding novel restorative agents free of harmful products, scientists and experimenters have recently focused on a variety of valuable, mostly medicinal stores.(12). Traditional diabetes treatments can have some serious side effects. For example, the most commonly used antidiabetic medications, such as thiazolidinedione and sulfonylureas, cause weight gain.

Additionally, biguanide and α -glucosidase remedies may have adverse effects on the gastrointestinal tract (13). Vibrant medicinal stores have been recognized as antidiabetic agents through the identification and separation of new bioactive secondary metabolites.

Types of diabetes

1. Type 1 diabetes
2. Type 2 diabetes
3. Gestational diabetes

1 Type 1 Diabetes

Insulin-producing pancreatic β -cells are selectively destroyed in this chronic autoimmune disease (14). In the absence of vulnerable repression, transplanting the pancreas from binary benefactors to habitual diabetic binary donors is complicated by the increased heterogeneity of pancreatic lesions of β -cells that are momentarily destroyed and the development of massive insulinitis using insinuating T lymphocytes, which measures an amnestic autoimmune response (15). Juvenile-onset diabetes or insulin-dependent diabetes mellitus (IDDM) are common names for type 1 diabetes. Symptoms frequent urination, thirst, loss of weight, excessive exhaustion, acetone breath, nausea, vomiting, blurred vision, and genital itching.

2 Type 2 Diabetes

Adult-onset diabetes is another name for type 2 diabetes mellitus. The gradual deformity of the insulin clerk against the backdrop of insulin resistance. Individuals who have this kind of diabetes are consistently resistant to the effects of insulin (16). According to encyclopedias, it impacts five to seven percent of the global population. Exercise, hypoglycemic medications, and salutary remedies are typically used to control the issue (17). This is the most prevalent kind of diabetes mellitus and is mostly linked to rotundity, age, lack of activity, and a family history of the disease (18).

3 Gestational Diabetes

Women who are pregnant Diabetes is a common condition. Large amounts of hormones are produced during pregnancy, and these hormones may cause insulin resistance by decreasing the body's ability to use insulin. Gravid diabetes mellitus is the term used to describe women who develop diabetes mellitus during pregnancy as well as those who have undetected asymptomatic type 2 diabetes mellitus that is found during pregnancy (18). Because GDM is linked to substantial maternal and fetal morbidity, it has clinical significance (19).

Other types of diabetes

1 Diabetes LADA-

Adult-onset, diabetes-associated autoantibodies, and the lack of insulin therapy need for a while after diagnosis are characteristics of adult-onset autoimmune diabetes (20). It's becoming clear that certain adults may have a slowly progressing form of Type 1 diabetes, which is identifiable by the presence of autoantibodies. A slow-progressing variant of type 1 diabetes, also known as LADA, may be present in certain individuals with type 2 diabetes who quickly develop an insulin dependence.

2 Diabetes MODY-

Maturity onset diabetes of the youthful is an autosomal dominantly inherited type of diabetes that originates from heterozygous mutations in key recap factors operating in the growth and development of pancreatic β - cells. Autosomal heritage, early onset of diabetes, absence of insulin resistance or autoimmune symptoms, and retention of endogenous insulin stashing are characteristics of MODY (21).

3 Double diabetes

The condition known as double diabetes is defined by hyperglycemia in children and young adolescents who have both type 1 and type 2 diabetes designations.

4 Brittle diabetes

Diabetes type 1 is an inherently unstable illness. A small percentage of type 1 diabetes patients, mostly young women, have poor metabolic control over time. They are marked by extreme glycemic insecurity and frequent, fluctuating hypoglycemic or diabetic ketoacidosis episodes that are not attributable to the patients' or clinicians' actions. The frequency of acute events, hospital reclamations, and the unexpected emergence of chronic problems significantly impair the quality of life for these patients. Brittle diabetes is the name given to this clinical disorder.

5 Diabetes Insipidus

Diabetes insipidus is a condition when excessive amounts of diluted urine are expelled as a result of excessive water intake, AVP resistance, or vasopressin insufficiency. The symptoms of polyuria include a urine volume greater than 21 m²/24 h, or around 150 ml/kg/24 h at birth, 100–110 ml/kg/24 h till the age of two, and 40–50 ml/kg/24 h in older children and adults (22).

Neonatal diabetes mellitus

- The first six months of life are when it happens.
- One gene flaw
- Insufficient insulin production
- Avoid gaining weight more quickly than you anticipated.
- High plasma glucose can be mistaken for type 1 diabetes symptoms and causes.

Symptoms of diabetes include

- Increased urination and thirst
- A rise in appetite
- Weariness
- Vision blur
- tingling or numbness in the hands or feet
- Sores without a head
- Unaccounted-for weight loss
- Ketones are a consequence of muscle and fat breakdown that occurs when there is insufficient insulin available, and they can be seen in urine.
- recurring infections, including vaginal, skin, or mouth infections; male sexual problems

Causes of diabetes include-

- Being overweight
- Too much glucocorticoid
- Overproduction of growth hormone
- Ovarian polycystic disorders
- Insulin receptor mutation
- [20] lipodystrophy

Causes of type 1 diabetes

1. An inherited predisposition to type 1 diabetes
2. Some viruses (like the mumps or German measles)
3. Environmental aspects

Causes of type 2 diabetes

When the pancreas quits making enough insulin or the body becomes resistant to it, type 2 diabetes occurs.

Diagnostic tests for diabetes mellitus

To identify prediabetes and diabetes, three blood tests are available.

1. Random plasma test or casual plasma (blood) glucose
2. Casual plasma (blood) glucose or random plasma test
3. Test of oral glucose tolerance

Casual plasma (blood) glucose/ random plasma test

The most straightforward test that doesn't require fasting prior to administration (19). With this test, a blood glucose level of 200 mg/dl or more and the presence of diabetes symptoms are required for a diagnosis of diabetes (23).

Fasting plasma glucose (FPG)

A 2-hour tube glucose value of ≥ 11.1 mmol/L in a 75g oral glucose forbearance test (OGIT) most closely correlates with a fasting tube glucose position of 7.0 mmol/L, and both indicate the onset of retinopathy (24). This should be taken after eight hours of dieting. A diabetes diagnosis is confirmed if blood glucose levels are greater than 126 mg/dl on two or more separate tests performed on different days (19).

Oral glucose tolerance test

A 2-hour blood glucose level of 200 mg/dl or above is considered prediabetes; a range between 140 and 199 mg/dl is considered prediabetes [23].

Hemoglobin A1C (HbA1c)

A1C is more accessible than FPG or 2hPG in a 75g OGIT and can be taken at any time of day. Because A1C represents the average tube glucose (PG) over the previous two to three months, it also eliminates the issue of daily fluctuation of glucose levels (24). $HbA1c \geq 6.5$ has sufficient particularity to support a diabetes diagnosis, while $HbA1c < 5.7$ has sufficient perceptivity to support a rejection of a diabetes diagnosis.

How do herbs work?

The precise ingredient that has a corrective impact on most sauces is unknown. There are many components in whole sauces, and it's likely that they combine to provide the desired therapeutic effect. A factory's variables will be influenced by the climate, insects, and soil quality of the area where it was built, as well as by the manner and timing of its collection and reuse (25).

What is herbal medicine good for?

Asthma, eczema, premenstrual syndrome, rheumatoid arthritis, migraine, menopausal symptoms, chronic fatigue, and irregular bowel patterns are just a few of the illnesses that herbalists treat. It is advisable to take herbal remedies under a qualified professional's supervision. Before tone-treating, make sure to consult your croaker or a herbalist. The following lists a few common or garden sauces along with their uses. For thorough descriptions of applications, potential hazards, side effects, and implicit relationships, please refer to our research on various sauces (25).

Herb–drug interaction and its mechanisms of action

When two or more medications are used together, there is a chance that chemical or pharmacological relationships will develop. Similar relationships may alter either agent's sequel, resulting in decreased or increased forcefulness or rigidity of adverse goods. Similar to the physicochemical makeup of the medications being used and their pharmacokinetic and pharmacodynamic interactions, the problems rely on a variety of chemical and pharmacological procurators (Fig. 3). Even while the mechanisms behind the relationships between sauces and medications are similar, they get more complex when multiple combinations are involved. Clinical security and efficacy may be impacted by herb-medicine relations (HDI) through cumulative, synergistic, or antagonistic relationships between herbal components and medicinal

molecules. However, hostile or hazardous relationships typically allow for more focus. Because of security concerns, HDI-convicted cumulative/synergistic products may improve the requested pharmacological sequel.




Figure 2 mechanisms of action of herb–drug interactions

For example, it has been demonstrated that agrimony increases the race glucose-lowering side effect of antidiabetic medications (26). Several mechanisms, including quantitative variations in renal concurrence (27, 28), bioavailability (29), medication division (30, 31), immersion (32–33), and elimination processes (34), may be linked to pharmacokinetic HDIs. Particularly the cytochrome P450 (CYP450) isoenzyme blood, hepatic metabolic enzyme systems continue to be a frequent or garden pharmacokinetic HDI route. Many anti-diabetic medications, such as pioglitazone, repaglinide, and rosiglitazone for CYP2C8, glibenclamide, glimepiride, glipizide, nate glinide, and rosiglitazone for CYP2C9, proguanil for CYP2C19, and pioglitazone and repaginate for CYP3A4 (35–36), are substrates of CYP450 isoenzymes. Many sauces have also been suggested to have an impact on the CYP450 system. For example, ginkgo inhibits CYP3A4, CYP2C9, and CYP2C19, while St. John's wort inhibits CYP2C and CYP3A (37). Through products on vibrant organs, receptor sites, or enzymes, pharmacodynamic HDIs can qualitatively characterize the behavior of the medication or condiment. Similar relationships can influence cumulative, synergistic, or negative goods. Many herbal medications, for example, contain antioxidant components that may help lower oxidative pressure, a major pathogenic cause of diabetes (38–39).

Antidiabetic pharmaceutical and herbal interventions

Common antidiabetic

Currently, a number of groups of pharmaceutical instruments are used to treat diabetes through different mechanisms, such as increasing insulin release (sulfonylureas, for example), decreasing hepatic glucose levels, and improving supplemental glucose absorption (biguanides, for example) (40–41). Some commonly used antidiabetic medications contain biguanides, such as metformin (by directly affecting insulin defiance), thiazolidinediones (by perfecting insulin defiance), vildagliptin and other related "gliptins" (by blocking DPP-4, an enzyme that breaks down the incretin GLP-1), and α -glucosidase inhibitors, such as acarbose and miglitol (by delaying the digestion of daedal carbohydrates). By binding to the sulfonylurea receptor subunit and inhibiting the K-ATP channel, other diabetes instruments prey on pancreatic beta-cell receptors and encourage the release of insulin (42, 43). Additionally, combination treatments—such as thiazolidinedione with glucosidase inhibitors and sulfonylureas with biguanides—are often used to increase the scope of therapeutic action, improve efficacy, and reduce adverse effects.

Herbs with antidiabetic properties

Diabetes and its related diseases are being treated using an increasing number of pharmacies. More than 1300 shop species are listed in the current NAPRALERT database, which defines more than 750 rubrics over 190 families. These range from less complex shops like fungi and algae to almost every kind of sophisticated shop. In traditional medicine, many of these stores have been used ethnopharmacologically as antidiabetic medications, particularly for type 2 diabetes (44, 45). While several of these shops have been experimentally researched to support their physiological

exertion, less research has been done on the chemical and pharmacological packages supporting the anti-diabetic exertion. Daedal carbohydrates, alkaloids, glycopeptides, terpenoids, peptides, amines, steroids, flavonoids, lipids, coumarins, sulfur composites, and inorganic ions are among the many potentially bioactive molecules that have been insulated and connected. Examples of common or garden sauces and beneficial compounds that have been used to treat diabetes include l-carnitine, vanadium, chromium, vitamin E, Momordicacharantia, Trigonellafoenum-graceum, Gymnemasylvestre, and Azadirachtolides (44). The suggested mechanisms of action supporting these composites' antidiabetic effects directly affect insulin storage, hepatic glycolysis and glycogenesis activation, adrenomimeticism, pancreatic beta cell potassium channel blocker activity, campsite activation, and intestinal glucose absorption modulation (46–47).

Common herb–drug interactions in diabetes

Co-administration of pharmaceutical instruments and antidiabetic sauces may impact HDIs, resulting in adverse medication events, such as hypoglycemia, dropped pharmaceutical goods, or meliorated goods (which may be clinically dishy). A succinct discussion of common or garden antidiabetic sauces and their implied relationships with antidiabetic instrumentalities is given in the section that follows. Up to June 2017, literature searches were carried out using Google Scholar and PubMed. The selection of pharmacies for inclusion is based on their lengthy history of harmonious use as well as the energy of readily available data on forcefulness or adverse/synergistic goods.

Momordica charantia

Momordica charantia, commonly referred to as karela or the bitter guard, is a blood Cucurbitaceae wine that unfolds. Ayurvedic and other traditional medication systems typically use the condiment as an anti-diabetic treatment. The factory is widely established in South America, East Africa, India, and Asia (48).

Phytochemistry of M. charantia

Similar components to glycosides, saponins, alkaloids, reducing sugars, resins, phenolic compounds, fixed oil paints, and free acids are abundant in bitter melon (50). Charantine, charine, momordicin, momordin, cucurbitins, cucurbitacins, momorcharins, etc. are the primary phytoconstituents found in M. charantia today (48). Charantin is responsible for the majority of M. charantia's anti-diabetic potential. The emulsion's hypoglycemic effect is comparable to that of insulin (51).

Mechanism of action

M. charantia uses a variety of methods to produce its hypoglycemic effects. Insulin stashing and glycogen conflation are major contributors to M. charantia's practical mechanism of hypoglycemic effect (49, 48). According to some research, bitter melon may increase hepatic glycogen concatenation, limit intestinal glucose uptake, and accelerate glucose application by supplementary and cadaverous brawn (48). According to Hsin-Yi Lo et al., an extract from M. charantia seeds significantly controls glucose metabolism through the insulin signaling pathway (52). Hsueh-ling Cheng linked and reported that triterpenoids are the implicit hypoglycemic instrumentalities responsible for the factory's anti-diabetic action in an experimental study using the cell-grounded webbing assay. AMP-actuated protein kinase was also identified as the initial mediator to initiate the action (53); (Fig. 4).

Antidiabetic effects of M. charantia

The hypoglycemic consequence of M. charantia on models of colorful beasts has been confirmed by experimental investigations. Methanolic conclusion extract of M. charantia was shown to exhibit cure-dependent hypoglycaemic exertion in alloxan-induced diabetic stoolies (54). The antidiabetic effect of M. charantia conclusion juice in streptozotocin-convincing diabetic stoolies was investigated by Mahmoud MF et al. (55). Joo-Hui Han et al. isolated four novel cucurbitane-type triterpenoids (C1–C4) from the ethanol extract of M. charantia in an exploratory study and investigated whether the composites had an impact on insulin perceptivity in both in vitro and in vivo models. Emulsion C2 was found to significantly reduce race glucose position and meliorated glycogen storeroom in STZ-fitted mensches (56).




Figure 3 Schematic representation of Probable molecular mechanism for anti-diabetic effect of *M. charantia*

Curcuma longa

According to reports, *Curcuma longa* Linn, a member of the blood Zingiberaceae, is a powerful condiment used in Ayurvedic medicine to treat diabetes. It is commonly referred to as haridra, haldi, or turmeric. The spice is indigenous to India and is widely produced, particularly in Maharashtra, Tamil Nadu, and West Bengal (57).

Phytochemistry of *C. longa*

A large number of phenolic composites are found in *C. longa* rhizomes. The main active components found in rhizomes nowadays are curcuminoids. Three related compounds, videlicet curcumin, demethoxycurcumin, and bisdemethoxycurcumin, are mixed together to form curcuminoids, which together make up roughly 60 of the total curcuminoids. The primary active ingredient that gives *C. longa* its maximum natural exertion is curcumin (57).

Mechanism of action *C. longa*

is known to exert its hypoglycemic effect through a variety of different mechanisms, the most popular or prevalent of which is the inhibition of the enzymes α -glucosidase and α -amylase (58,59,60). AKT phosphorylation and GLUT4 translocation in cadaverous muscles may be the practical mechanism behind curcumin's antidiabetic effect, according to Gutierrez et al. (61). According to Kuroda et al., the PPAR- γ ligand-list exertion of the emulsion is largely responsible for the hypoglycemic sequelae that curcumin, demethoxycurcumin, bisdemethoxycurcumin, and ar-turmerone produce (62). Yasser et al. found in a molecular docking research that curcumin's hypoglycemic effects might be caused by inhibiting glycogen synthase kinase 3 β (64); Fig. 5).

Antidiabetic effect of *C. longa*

Colorful investigations have demonstrated the hypoglycemic effect of *C. longa* rhizomes. Seo et al. investigated curcumin's potential to reduce blood sugar in diabetic db/dbmensch. Curcumin-treated animals showed a notable decrease in both race glucose and HbA1c levels. Another investigation found that curcumin treatment improved glucose homeostasis, glucose forbearance, and raised plasm insulin levels (63). According to one investigation, an ethanolic extract of *C. longa* suppressed swollen race glucose circumstances in genetically diabetic KK-Ay Mensch (62).




Figure 5 Schematic representation of Probable molecular mechanism for anti-diabetic effect of *C. longa*

Trigonella foenumgraceum

Fenugreek, or *Trigonella foenumgraceum*, is mainly used as a voluntary treatment for diabetes. The factory, a member of the Fabaceae family, originated in North Africa and India. Ayurvedic and folklore drugs have long used the condiment as a powerful anti-diabetic medication (57, 65). (Figure 6)

Phytochemistry of *T. foenumgraceum*

The majority of the phytochemical investigations have focused on seeds. Seeds are mostly composed of alkaloids (around 36), steroidal saponins, gum, and filaments (65). Trigonelline, one of the main phytoconstituents in fenugreek seed's alkaloid content, is what gives the condiment its greatest potency. A significant amount of the gum (25–30) is galactomannan. About 0.1 to 2.2 are steroidal saponins, which are comparable to diosgenin and yamogenin. The seeds also contain fenugreekine, a saponin peptide ester. Today, 4-hydroxyisoleucine, one of the free amino acids found in seeds, has been shown to directly stimulate insulin (57, 66).

Mechanism of action

The plant works by promoting insulin secretion and the regeneration of pancreatic β cells [67, 68]. According to a study, trigonelline has a hypoglycemic effect by inhibiting the activity of glycogen synthase kinase isoforms, which regulate glycogen metabolism [66]. Trigonelline has also been shown to boost the insulin signaling pathway, which in turn improves glucose and lipid hemostasis [60]. *T. foenum graecum* may also work by inhibiting glucose absorption, improving insulin resistance, and GLUT-4 translocation [70, 71]; see Fig. 6.

Antidiabetic effects of *T. foenum graecum*

Pharmacological investigations have demonstrated the potential anti-diabetic effects of colored *T. foenum graecum* extracts. A study examined the anti-diabetic effects of fenugreek seed ethanolic extract on streptozotocin-convicted diabetic stoolies. In diabetic stoolies, the effects showed a large increase in blood insulin and a significant decrease in serum glucose, grand cholesterol, and triacylglycerol (72). Trigonelline's hypoglycemic aftereffects in alloxan-convicted diabetic menstrual patients were investigated by Shah et al. They related the presence of island cells in the pancreatic conduit to its beneficial repercussion on β cells and showed a decrease in *in vivo* glucose position (73).

Numerous studies conducted by researchers on seed extracts, raw greaspaint, and active compounds have shown the condiment's hypoglycemic impact, confirming its usage as a powerful herbal treatment for diabetes.




Figure 6 Schematic representation of Probable molecular mechanism for anti-diabetic effect of *T. foenum-graecum*

Clinical studies

Clinical trials are crucial for determining a personal medication's safety and effectiveness in people. Only current papers from 2010 onward have been connected from the database search, which is based on the literature found on the clinical effectiveness of the five sauces. The specifics of clinical trials for the five sauces' antidiabetic products have been summed up in

REFERENCES

- [1]. Kharroubi AT, Darwish HM. Diabetes Mellitus: The Epidemic of the Century. *World J Diabetes* (2015) 6:850–67. doi: 10.4239/wjd.v6.i6.850
- [2]. Hunter SJ, Garvey WT. Insulin Action and Insulin Resistance: Diseases Involving Defects in Insulin Receptors, Signal Transduction, and the Glucose Transport Effector System 1. *Am J Med* (1998) 105(4):331–45. doi: 10.1016/S0002-9343(98)00300-3
- [3]. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. *Diabetes Care* (2004) 27(5):1047–53. doi: 10.2337/diacare.27.5.1047
- [4]. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* (2014) 37 Suppl 1:S81–90. doi: 10.2337/dc14-S081
- [5]. Patel DK, Prasad SK, Kumar R, Hemalatha S. An Overview on Antidiabetic Medicinal Plants Having Insulin Mimetic Property. *Asian Pac J Trop Biomed* (2012) 2:320–30. doi: 10.1016/S2221-1691(12)60032-X
- [6]. Cakan N, Kizilbash S, Kamat D. Changing Spectrum of Diabetes Mellitus in Children: Challenges With Initial Classification. *Clin Pediatr (Phila)* (2012) 51:939–44. doi: 10.1177/0009922812441666
- [7]. Li GQ, Kam A, Wong KH, Zhou X, Omar EA, Alqahtani A, et al. Herbal Medicines for the Management of Diabetes. In: Ahmad SI, editor. *Diabetes: An Old Disease, a New Insight, Advances in Experimental Medicine and Biology*. New York, NY: Springer (2013). p. 396–413. doi: 10.1007/978-1-4614-5441-0_28

- [8]. . Kazeem MI, Davies TC. Anti-Diabetic Functional Foods as Sources of Insulin Secreting, Insulin Sensitizing and Insulin Mimetic Agents. *J Funct Foods* (2016) 20:122–38. doi: 10.1016/j.jff.2015.10.013
- [9]. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care* (2009) 32(suppl 2):S157–63. doi: 10.2337/ dc09-S30220.
- [10]. .Fakhruddin S, Alanazi W, Jackson KE. Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury. *J Diabetes Res* (2017) 2017. doi: 10.1155/2017/8379327
- [11]. Mohd Nor NA, Budin SB, Zainalabidin S, Jalil J, Sopian S, Jubaidi FF, et al. The role of polyphenol in modulating associated genes in diabetes-induced vascular disorders. *Int J Mol Sci* (2022) 23(12):6396.
- [12]. Dey L, Attele AS, Yuan C-S. Alternative therapies for type 2 diabetes. *Altern Med Rev* (2002) 7(1):45–58.
- [13]. Wadkar K, et al. Antidiabetic potential and Indian medicinal plants. *J herbal Med toxicology*. (2008) 2(1):45–50.
- [14]. Ozougwu J.C, Obimba K.C, Belonwu C.D and Unakalamba C.B, “The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus”, *Journal of Physiology and Pathophysiology* 2013; 4(4):46-57.
- [15]. Deepti B, Sowjanya K, Lidiya B, Bhargavi RS and Babu P.S, “A modern review on Diabetes mellitus: An inhibitory metabolic disorder”, *Journal of in silico and in vitro Pharmacology* 2017; 3:1-14.
- [16]. Deepti B, Sowjanya K, Lidiya B, Bhargavi RS and Babu P.S, “A modern review on Diabetes mellitus: An inhibitory metabolic disorder”, *Journal of in silico and in vitro Pharmacology* 2017; 3:1-14.
- [17]. Bastaki S., “Diabetes mellitus and its treatment”, *International Journal of Diabetes and Metabolism* 2005; 13:111-134.
- [18]. Bastaki S., “Diabetes mellitus and its treatment”, *International Journal of Diabetes and Metabolism* 2005; 13:111-134.
- [19]. Siddiqui A.A., Siddiqui S.A., Ahmad S, Siddiqui S, Ahsan I. and Sahu K., “Diabetes: mechanism, pathophysiology and management- A review”. *International Journal of Drug Development and Research* 2013; 5(2):1-23.
- [20]. Laugesen E., Ostergaard J.A.and R. DG Leeslie R.D., “Latent autoimmune diabetes of the adult-current knowledge and uncertainty”. *Diabetic Medicine* 2015.
- [21]. Anik A, Latli G, Abaci A., and Bober E., “Maturity onset diabetes of the young (MODY): An update”. *Journal of Pediatric Endocrinology and Metabolism* 2015; 28(3-4):251-263.
- [22]. Dilorgi N, Napoli F and Elsa A, “Maria Allergi, Irene Olivieri, Enrica Bertelli et al. Diabetes Insipidus – diagnosis and management”. *Journal of Hormone Research in Pediatrics* 2012; 77: 69-84.
- [23]. Harikumar K., Kumar B.K., Hemalatha G.J., Kumar M.B. and Steven Fransis Saky Lado S.F., “A review on diabetes mellitus”, *International Journal of Novel Trends in Pharmaceutical Sciences* 2015; 5.
- [24]. Goldenberg R. and Punthakee Z., “Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome”, *Canadian Journal of Diabetes* 2013; 37: S8-S11.
- [25]. Pritesh Patel, Pinal Harde, Jagath Pillai, Nilesh Darji And Bhagirath Patel Sat Kaival College Of Pharmacy Pharmacophore (An International Research Journal Antidiabetic Herbal Drugs A Review Available Online At Review Article Pharmacophore, 2012; Vol. 3 , 18-29.
- [26]. Gray AM, Flatt PR. Actions of the traditional anti-diabetic plant, Agrimony eupatoria (agrimony): effects on hyperglycaemia, cellular glucose metabolism and insulin secretion. *Br J Nutr*. 1998;80(1):109–14.
- [27]. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. *Am J Kidney Dis*. 2004;44(1):1–11.
- [28]. Al-Ali M, Wahbi S, Twaij H, Al-Badr A. Tribulus terrestris: preliminary study of its diuretic and contractile effects and comparison with Zea mays. *J Ethnopharmacol*. 2003;85(2–3):257–60.
- [29]. . Colalto C. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. *Pharmacol Res*. 2010;62(3):207–27.
- [30]. Rodriguez-Landa JF, Contreras CM. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. *Phytomed Int J PhytotherPhytoPharmacol*. 2003;10(8):688–99.

- [31]. Lambrecht JE, Hamilton W, Rabinovich AA. Review of herb–drug interactions: documented and theoretical. *US Pharmacist*. 2000;25:42–53.
- [32]. Mochiki E, Yanai M, Ohno T, Kuwano H. The effect of traditional Japanese medicine (Kampo) on gastrointestinal function. *Surg Today*. 2010;40(12):1105–11.
- [33]. Qi QH, Wang J, Liang GG, Wu XZ. Da-Cheng-Qi-Tang promotes the recovery of gastrointestinal motility after abdominal surgery in humans. *Dig Dis Sci*. 2007;52(6):1562–70.
- [34]. Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF. Drug-herb interactions: eliminating toxicity with hard drug design. *Curr Pharm Des*. 2006;12(35):4649–64.
- [35]. Purwantiningsih HAH, Ismail S, Chan KL. Inhibitory effect of *Eurycoma longifolia* extract and eurycomanone on human cytochrome p450 isoforms. *Int J Pharm Sci*. 2014;6:441–4.
- [36]. Purwantiningsih HAH, Ismail S, Chan KL. Inhibitory effect of *Eurycoma longifolia* extract and eurycomanone on human cytochrome p450 isoforms. *Int J Pharm Sci*. 2014;6:441–4.
- [37]. Mills E, Montori V, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St John’s wort with conventional drugs: systematic review of clinical trials. *Br Med J*. 2004;329:27–30.
- [38]. Nasri H, Shirzad H, Baradaran A, Rafeian-Kopaei M. Antioxidant plants and diabetes mellitus. *J Res Med Sci*. 2015;20(5):491–502.
- [39]. Bahmani M, Zargaran A, Rafeian-Kopaei M, Saki K. Ethnobotanical study of medicinal plants used in the management of diabetes mellitus in the Urmia, Northwest Iran. *Asian Pac J Trop Med*. 2014;7S1:S348–54.
- [40]. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA*. 1999;281(21):2005–12.
- [41]. Hermann LS, Lindberg G, Lindblad U, Melander A. Efficacy, effectiveness and safety of sulphonylurea–metformin combination therapy in patients with type 2 diabetes. *Diabetes Obes Metab*. 2002;4(5):296–304.
- [42]. Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. *Diabetes Res Clin Pract*. 2004;63(2):127–34.
- [43]. Del Prato S, Bianchi C, Marchetti P. Beta-cell function and anti-diabetic pharmacotherapy. *Diabetes Metab Res Rev*. 2007;23(7):518–27.
- [44]. Chang CL, Lin Y, Bartolome AP, Chen YC, Chiu SC, Yang WC. Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. *Evid Based Complement Altern Med eCAM*. 2013;2013:378657.
- [45]. Mishra R, MohdShuaib S, Shiravan S, Mishra PS. A review on herbal antidiabetic drugs. *J App Pharma Sci*. 2011;01:235–7.
- [46]. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. *Asian Pac J Trop Biomed*. 2012;2(4):320–30.
- [47]. Hong SH, Heo JI, Kim JH, Kwon SO, Yeo KM, Bakowska-Barczak AM, Kolodziejczyk P, Ryu OH, Choi MK, Kang YH, et al. Antidiabetic and Beta cell-protection activities of purple corn anthocyanins. *Biomol Ther (Seoul)*. 2013;21(4):284–9.
- [48]. Joseph B, Jini D. Antidiabetic effects of *Momordica charantia* (bitter melon) and its medicinal potency. *Asian Pac J Trop Dis*. 2013;3(2):93–102.
- [49]. Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I. Hypoglycemic activity of the fruit of the *Momordica charantia* in type 2 diabetic mice. *J Nutr Sci Vitaminol*. 2001;47(5):340–4.
- [50]. Saeed MK, Shahzadi I, Ahmad I, Ahmad R, Shahzad K, Ashraf M, et al. Nutritional analysis and antioxidant activity of bitter gourd (*Momordica charantia*) from Pakistan. *Pharmacologyonline*. 2010;1:252–60.
- [51]. Budrat P, Shotipruk A. Extraction of phenolic compounds from fruits of bitter melon (*Momordica charantia*) with subcritical water extraction and antioxidant activities of these extracts. *Chiang Mai J Sci*. 2008;35(1):123–30.
- [52]. Lo H, Ho T, Lin C, Li C, Hsiang C. *Momordica charantia* and Its Novel Polypeptide Regulate Glucose Homeostasis in Mice via Binding to Insulin Receptor. *J Agric Food Chem*. 2013;61:2461–8.

- [53]. Hsueh-Ling C, Hsin-Kai H, Chi -IC, Chung-Pao T, Chang-Hung C. A Cell-Based Screening Identifies Compounds from the Stem of *Momordica charantia* that Overcome Insulin Resistance and Activate AMP-Activated Protein Kinase. *J Agric Food Chem*. 2008;56:6835–43.
- [54]. Nkambo W, Anyama NG, Onegi B. In vivo hypoglycemic effect of methanolic fruit extract of *Momordica charantia* L. *Afr Health Sci*. 2013;13(4):933–9.
- [55]. Mahmoud MF, El Ashry FE, El Maraghy NN, Fahmy A. Studies on the antidiabetic activities of *Momordica charantia* fruit juice in streptozotocin-induced diabetic rats. *Pharm Biol*. 2017;55(1):758– 65.
- [56]. Han JH, Tuan NQ, Park MH, Quan K, Oh J, Heo KS, et al. Cucurbitane Triterpenoids from the Fruits of *Momordica Charantia* Improve Insulin Sensitivity and Glucose Homeostasis in Streptozotocin-Induced Diabetic Mice. *Mol Nutr Food Res*. 2018;62(7):1700–769.
- [57]. Khare CP. *Indian Medicinal Plants An Illustrated Dictionary*. Berlin: Springer. 2008.
- [58]. Riyaphan J, Jhong C, Lin S, Chang C, Tsai M, Lee D, et al. Hypoglycemic efficacy of docking selected natural compounds against α -Glucosidase and α -Amylase. *Molecules*. 2018;23:2260.
- [59]. Ghani U. Re-exploring promising α -glucosidase inhibitors for potential development into oral anti-diabetic drugs: Finding needle in the haystack. *Eur J Med Chem*. 2015;103:133–62.
- [60]. Jhong C, Riyaphan J, Lin J, Chia Y, Weng C. Screening α -glucosidase and α -amylase inhibitors from natural compounds by molecular docking in silico. *BioFactors*. 2015;41(4):242–51.
- [61]. Gutierrez V, Campos M, Arcaro C, Assis R, Baldan-Cimatti H, Peccinini R, et al. Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). *Evid Based Complement Alternat Med*. 2015;1–13.
- [62]. Kuroda M, Mimaki Y, Nishiyama T, Mae T, Kishida H, Tsukagawa M, et al. Hypoglycemic Effects of Turmeric (*Curcuma longa* L. Rhizomes) on Genetically Diabetic KK-Ay Mice. *Biol Pharm Bull*. 2005;28(5):937–9.
- [63]. Seo K, Choi M, Jung U, Kim H, Yeo J, Jeon S, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. *Mol Nutr Food Res*. 2008;52:995–1004.
- [64]. Bustanji Y, Taha MO, Almasri IM, Al-Ghoussein M, Mohammad MK, Alkhatib HS. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. *J Enzyme Inhib Med Chem*. 2009;24(3):771–8.
- [65]. Bahmani M, Shirzad H, Mirhosseini M, Mesripour A, RafieianKopaei M. A Review on Ethnobotanical and Therapeutic Uses of Fenugreek (*Trigonella foenum-graceum* L). *Evid Based Complement Alternat Med*. 2016;21(1):53–62.
- [66]. Roshana Devi V, Sharmila C, Subramanian S. Molecular Docking Studies Involving the Inhibitory Effect of Gymnemic Acid, Trigonelline and Ferulic Acid, the Phytochemicals with Antidiabetic Properties, on Glycogen Synthase Kinase 3 (α and β). *J Appl Pharm Sci*. 2018;8(04):150–60.
- [67]. Yoshinari O, Igarashi K. Anti-Diabetic Effect of Trigonelline and Nicotinic Acid, on KK-Ay Mice. *Curr Med Chem*. 2010;17:2196– 202.
- [68]. Zhou J, Zhou S, Zeng S. Experimental diabetes treated with trigonelline: effect on β cell and pancreatic oxidative parameters. *Fundam Clin Pharmacol*. 2011;27(3):279–87.
- [69]. Amat-Alrazaq A, Aldakinah, Muhammad Y, Al-Shorbagy, Dalaal M, Abdallah, et al. Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway. *J Pharm Pharmacol*. 2017:1–9.
- [70]. Jaiswal N, Maurya CK, Venkateswarlu K, Sukanya P, Srivastava AK, Narender T, Tamrakar AK. 4-Hydroxyisoleucine stimulates glucose uptake by increasing surface GLUT4 level in skeletal muscle cells via phosphatidylinositol-3-kinase-dependent pathway. *Eur J Nutr*. 2012;51(7):893–8.
- [71]. Maurya CK, Singh R, Jaiswal N, Venkateswarlu K, Narender T, Tamrakar AK. 4-Hydroxyisoleucine ameliorates fatty acid-induced insulin resistance and inflammatory response in skeletal muscle cells. *Mol Cell Endocrinol*. 2014;395(1–2):51–60.
- [72]. Eidia A, Eidib M, Sokhteha M. Effect of fenugreek (*Trigonella foenum-graceum* L) seeds on serum parameters in normal and streptozotocin-induced diabetic rats. *Nutr Res*. 2007;27:728–33.

- [73]. Shah SN, Bodhankar SL, Badole SL, Kamble HV, Mohan V. Effect of trigonelline: An active compound from *Trigonella foenum graecum* Linn. In alloxan induced diabetes in mice. *Cell Tissue Res.* 2006;6(1):585–90.